We develop transformative medicines and technologies by building agile, focused companies called Vants.

Matthew Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Eric Venker serves as President and Chief Operating Officer of Roivant Sciences. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.

Mayukh Sukhatme serves as President and Chief Investment Officer of Roivant. In that role he oversees the creation and support of biopharmaceutical companies in the Roivant family. Dr. Sukhatme joined Roivant in 2015 and previously served as Chief Business Officer and President of Roivant Pharma.

From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.

Frank Torti is the Vant Chair at Roivant Sciences. Dr. Torti serves as Chairman of the Board of the companies in the Roivant Pharma family and is responsible for the management of those businesses. He previously served as Vant Investment Chair, where he oversaw a group of companies responsible for the development of thirty-five investigational drugs in eleven therapeutic areas and over fifty clinical trials, including four successful Phase 3 trials. Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today.

Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.

Amy Mahery has more than twenty years of experience in the biopharmaceutical industry. She has held diverse global and U.S. commercial leadership roles spanning sales, marketing, and market access where she has been involved in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunology. Amy previously held multiple leadership roles at EMD Serono, Inc (Merck KGaA). Most recently, she served as Senior Vice President and Head of Global Franchise, Neurology and Immunology (N&I) at EMD Serono where she developed and led the implementation of the end-to-end franchise strategy for the N&I portfolio. Prior to that, Amy led worldwide access strategy development across Oncology, Neurology, Immunology, Fertility, and General Medicines to create advanced approaches to pricing, reimbursement, and patient access as Senior Vice President and Head of Global Market Access and Pricing. Amy holds a holds a B.S. in Neuroscience from Trinity College.

Srini Ramanathan, Ph.D., has worked in the biotechnology industry over 20 years and has been involved in drug approvals across ophthalmology, oncology and virology. Dr. Ramanathan was previously at Horizon Therapeutics, where he was Senior Vice President of Research and Development Sciences, with portfolio oversight of discovery, preclinical development, translational, and several development functions; he also oversaw scientific due diligence for business development evaluations. Before joining Horizon, Dr. Ramanathan served as Senior Project Leader at AbbVie, overseeing the development of multiple immunology programs for rheumatology and gastrointestinal indications. Prior to AbbVie, he served as Global Head of Clinical Pharmacology at Gilead Sciences with portfolio responsibilities across all therapeutic areas. He has been involved in various diversity and inclusion initiatives, and served on the board of the non-profit organization Asian University of Women.

Dr. Ramanathan earned his Master of Science in pharmaceutics from Duquesne University and his doctorate in pharmaceutics from Rutgers University.

Richard Pulik serves as Chief Financial Officer of Roivant Sciences. Mr. Pulik joined Roivant in September 2021 and brings over twenty years of industry experience. Prior to joining Roivant, Mr.Pulik was the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions based in Basel, Switzerland. Earlier in his career Mr. Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector.

Mr. Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania in 2001. He grew up in Slovakia, Austria and Boston, and is passionate about delivering meaningful medicines to patients globally.

Rakhi Kumar serves as Chief Accounting Officer of Roivant Sciences. Ms. Kumar joined Roivant in September 2015, and previously served as Vice President, Finance and External Reporting. Prior to joining Roivant, Ms. Kumar was responsible for external reporting, corporate and technical accounting at The Medicines Company from 2013 to 2015. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young.

Ms. Kumar also serves as a director and as chair of the audit committee for NeuroPace (NASDAQ: NPCE), a medical device company dedicated to reducing debilitating seizures in patients with epilepsy. She is a licensed Certified Public Accountant and a Chartered Professional Accountant in Ontario, Canada. She received her M.S. in Accounting and Taxation from the University of Hartford.

Jo Chen is the General Counsel at Roivant, where he is responsible for Roivant's legal, compliance, and risk management functions.He was previously general counsel at JHL Capital Group.Jo has also been an attorney at Bain Capital, D.E.Shaw & Co., and the law firm of Weil, Gotshal & Manges.

He received a J.D. from Yale Law School and an A.B. from Princeton University.

Matt Maisak, Ph.D. serves as Chief Operating Officer, Roivant Platforms. Dr. Maisak joined the Roivant team in 2018. Prior to leading the Roivant Platforms, Dr. Maisak was a key member of the Axovant business development team, where he led the in-licensing efforts for the GM1 and GM2 gangliosidoses gene therapy programs from the University of Massachusetts. Prior to Roivant, Dr. Maisak held several strategic roles in Global Operations at Roche Diagnostics, where he worked across regulatory and manufacturing strategy.

Dr. Maisak earned a doctor of philosophy from the Max Planck Institute working under Dr. Axel Borst. During this time, he investigated the role single neuronal subtypes play in the computation of direction selective motion vision. His work was published in Nature and Current Biology and featured in popular science media such as National Geographic (Geo) and Bayerischer Rundfunk. Dr. Maisak studied medicine at Yale University School of Medicine.

Alex Gasner serves as the Executive Vice President of Roivant Health, where he leads new investments and company creation in healthtech. Mr. Gasner joined Roivant in November, 2017, and previously served as Head of Corporate Development, where he helped lead Roivant's $3b strategic alliance with Sumitomo Dainippon Pharma and the $200m investment from SK Holdings in our protein degradation platform.

Before Roivant, Mr. Gasner co-founded Bee, a retail financial services platform for low and middle-income Americans, building the company to 25,000 customers through a successful exit, after spending his early career as a management consultant. Mr. Gasner earned his B.S.E. cum laude in Mechanical Engineering from Princeton University.

Kelly Graff serves as Head of People at Roivant Sciences leading Human Resources and Talent Acquisition. Ms. Graff joined Roivant in 2020 and served in roles of increasing responsibility, most recently as Head of Talent Acquisition. Prior to joining Roivant, Ms. Graff worked as an executive recruiter with several boutique search firms focused on biotechnology and venture capital. Before making the pivot into life sciences, she worked in the U.S. defense and intelligence community.

Ms. Graff received her M.S. in International Relations from the University of Denver and B.S. in History from University of California, Davis.

Vivek Ramaswamy is our Founder and Chairman of our board of directors. He served as Chief Executive Officer of Roivant from May 2014 to January 2021. Mr. Ramaswamy previously served as a member of the investment team at QVT Financial, from 2007 to 2014. He was previously a director of Myovant Sciences, Axovant Sciences and Arbutus Biopharma. Mr. Ramaswamy received his A.B. in Biology from Harvard College and his J.D. from Yale Law School, where he was a Paul & Daisy Soros Fellow.

Andrew Lo has served as Director of Roivant since 2016. He is a Charles E. and Susan T. Harris Professor at MIT Sloan School of Management since 1988, Founder and Chairman of QLS Advisors since 2019, Member of Thalēs Advisory Board since 2019, Chairman Emeritus and Senior Advisor of AlphaSimplex Group since 2018 and member of the Competitive Market Advisory Counsel of the Chicago Mercantile Exchange since 2013. Dr. Lo has served as Director of BridgeBio Pharma since 2020 and advisor of the same company from 2015 to 2020.

Melissa Epperly has served as Director of Roivant since 2022. Ms. Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc. since September 2019. Prior to her current position, she served as Chief Financial Officer of PsiOxus Therapeutics Ltd., a clinical-stage gene therapy cancer company, from June 2018 to August 2019. Prior to that, Ms. Epperly also served as Chief Financial Officer and Head of Business Development at R-Pharm US, a commercial-stage oncology company, from October 2015 to June 2018. Ms. Epperly also served as a Director at Anchorage Capital Group, a credit-focused hedge fund from August 2012 to September 2015.

Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A. from Harvard Business School.

Ilan Oren has served as Director of Roivant since 2014. He has served as Co-Chief Executive Officer of Dexcel Pharma, a privately-owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as Co-CEO, Ilan served as Vice President for the group and led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments, and mergers and acquisitions. He holds an A.B. in Economics from Harvard College.

Daniel Gold has served as Director of Roivant since 2020. Mr. Gold serves as the CEO, managing partner and founder of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT Financial, through its managed and affiliated multi-strategy funds, is an experienced global investor in multiple industries, including biotech, financial, shipping and offshore industries. Mr. Gold founded QVT Financial LP in 2003. Mr. Gold holds an A.B. in Physics from Harvard College. Mr. Gold also currently serves on the board of public companies MP Materials, Okeanis Eco Tankers Corp. and Awilco Drilling PLC, in addition to various private companies.

Hiroshi Nomura has served as a Director of Roivant since 2022. Mr. Nomura has served as President and Chief Executive Officer and Representative Director of Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), a pharmaceutical company based in Japan, since April 2018. Before serving at his current position, Mr. Nomura also served in a number of executive leadership roles at Sumitomo Pharma, including as a member of the Board of Directors, Senior Executive Officer, Chief Finance Officer and Representative Director between April 2017 and April 2018, and as a member of the Board of Directors, Senior Executive Officer and Chief Finance Officer from April 2014 to April 2017. Before that, Mr. Nomura also held various other positions with increasing responsibilities at Sumitomo Pharma from October 2005 to April 2014. Mr. Nomura currently serves on the boards of directors of Myovant Sciences, Sumitomo Pharma, Sumitovant Biopharma and Sumitomo Pharma Oncology, Inc. Mr. Nomura received an economics degree from University of Tokyo.

James C. Momtazee has served as a Director of Roivant since September 2021. He has held various positions at KKR & Co., Inc. (“KKR”) since 1996. He helped form KKR's health care industry group in 2001 and was promoted to KKR's Head of the Heath Care Team for the Americas Private Equity platform in January 2009. He was a member of KKR's Americas Private Equity Investment Committee and was Chairman of the Health Care Strategic Growth and the Health Care Royalty & Income Investment Committees. During the period between 2001 and 2019, KKR was one of the most active investors on Wall Street, committing over $50 billion in capital across the health care sector. The largest of these investments was its $33 billion acquisition of HCA, Inc. in 2006, which at the time, was the largest cash buyout in history. During this same period, KKR made several other notable investments across the health care sector, including: Jazz Pharmaceuticals plc in 2004, PRA Health Sciences, Inc. in 2013, and BridgeBio Pharma, Inc. in 2016.

Mr. Momtazee currently serves on the Board of Directors of BridgeBio, Apollo Therapeutics, Kriya Therapeutics and the Medical Device Manufacturers Association and has previously served on the Board of Directors of multiple other health care companies, including PRA Health Sciences, Inc. (lead independent director), Envision Healthcare, Heartland Dental, Ajax Health, Global Medical Response, BrightSpring Health Services, Covenant Surgical Partners, Entellus Medical, Inc. (acquired by Stryker Corporation), EchoNous, Spirox, Inc., Arbor Pharmaceuticals, Lake Region Medical, HCA Healthcare, Jazz Pharmaceuticals, and Alliance Imaging.

Keith Manchester has served as Director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr. Manchester serves as a director for the following companies: Roivant Sciences Ltd., Roivant Sciences, Inc., Arbutus Biopharma Corporation, and Kriya Therapeutics. Dr. Manchester also sits on the Supervisory Board of Medigene AG.

Matt Maisak, Ph.D. serves as Chief Operating Officer, Roivant Platforms. Dr. Maisak joined the Roivant team in 2018. Prior to leading the Roivant Platforms, Dr. Maisak was a key member of the Axovant business development team, where he led the in-licensing efforts for the GM1 and GM2 gangliosidoses gene therapy programs from the University of Massachusetts. Prior to Roivant, Dr. Maisak held several strategic roles in Global Operations at Roche Diagnostics, where he worked across regulatory and manufacturing strategy.

Dr. Maisak earned a doctor of philosophy from the Max Planck Institute working under Dr. Axel Borst. During this time, he investigated the role single neuronal subtypes play in the computation of direction selective motion vision. His work was published in Nature and Current Biology and featured in popular science media such as National Geographic (Geo) and Bayerischer Rundfunk. Dr. Maisak studied medicine at Yale University School of Medicine.

Iván Cornella-Taracido is vice president of translational chemical biology at Roivant Discovery.

His team develops and leverages chemical biology and proteomics methods and workflows to support the discovery organization and translational assessment of clinical opportunities for target selection, biomarker identification, and indication expansion.

In previous roles, at Cedilla Therapeutics, Merck, AstraZeneca, and Sanofi, Iván established and managed chemical biology and proteomics teams, supporting target and drug discovery initiatives across disease areas and modalities. Before Sanofi, at Novartis, he was a founding member of the NIBR target identification and mode of action elucidation (TIDMoA) platform. Throughout his career, Iván has also acted as consultant on target and drug discovery for a number of start-ups and biotech firms.

Iván holds a Ph.D. in organic chemistry from the Universidade da Coruña, Spain, and earned an Executive Certificate in innovation from MIT Sloan School of Management. He completed postdoctoral work at the Institute of Chemistry & Cell Biology of Harvard Medical School (now the Broad Institute of MIT and Harvard), as National Cancer Institute Initiative for Chemical Genetics Research Fellow, and at the Boston College chemistry department.

Iván volunteers as committee member for the Chemistry in Cancer Research section of the AACR, and as ambassador for the non-profit organization SeedingLabs. He has been an invited speaker, organizer and chair for numerous international conferences on drug discovery, phenotypic screening, target identification, chemical biology and proteomics.

As chief technology officer, Huafeng oversees the development of new computational methods and models in the Roivant Discovery platform. He also provides guidance on their applications in drug discovery projects. Huafeng joined Silicon Therapeutics prior to its acquisition by Roivant Sciences.

Previously, Huafeng spent 12 years at D. E. Shaw Research, a privately held biochemistry research company based in New York, where he played an early role in the design of the specialized Anton chip for molecular dynamics simulations and led development of the methods and software for free energy calculations that are now widely used in the pharmaceutical industry. His research interests include development of simulation methods, free energy calculations, structural immunology, protein folding and misfolding and molecular design.

Huafeng earned a bachelor of science degree in chemistry from Peking University in Beijing, China and a master of science and a doctor of philosophy degree in chemical physics from Columbia University in New York."

Eric has more than 15 years drug discovery experience gained at small, mid-size and large pharma/biotech companies including Merck-Serono, Novartis, and AstraZeneca.

His experience spans several therapeutic areas and drug modalities, including small molecules, macrocycles, peptides, oligonucleotides, drug conjugates, and degraders, with a track record of delivering across discovery phases, including clinical candidates and novel technologies. At AstraZeneca, he built the first New Modalities group in the industry, which paved the way for the rapid expansion of the field, later fueled by protein degradation approaches. There, he also led a corporate-wide drug discovery transformation project, which brought large investments into multiple areas including the use of AI for drug discovery. Before joining Roivant, he built a first-in-category biotech company at Flagship Pioneering, leading the R&D team from inception, and demonstrated proof-of-concept for a new modality.

Eric is coauthor/coinventor of over 65 publications, patents, posters and oral presentations. He holds a doctor of philosophy degree in organic chemistry from the University of Edinburgh in Edinburgh and a master’s of business administration from Imperial College London in London.

Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to Roivant Discovery.

Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam.

Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.

As Vice President, Translational Informatics at Roivant Discovery, Tudor leads translational informatics efforts ranging from targets through drug discovery as we advance our pipeline of medicines to the clinic. Tudor joined Roivant Discovery from the University of New Mexico. Tudor is a digital drug hunter with three decades of experience in machine learning and knowledge management applied to target and drug discovery.

At the University of New Mexico, Tudor served as director for screening informatics and, ultimately as chief of translational informatics where he received over $24 million in extramural funding for a broad range of projects. Prior to the University of New Mexico, Tudor worked at AstraZeneca where he conceptually developed the “lead-like approach” for combinatorial chemistry and fragment-based drug discovery. Tudor co-invented the first G-protein coupled estrogen receptor agonist, an orphan drug designated compound for uveal melanoma. He has developed machine learning models since 1989, first in cheminformatics and quantitative structure-activity relationship (QSAR) and later in disease and target biology. Tudor has co-authored over 270 publications, edited two books on informatics in drug discovery, has been awarded 10 U.S. patents and has been cited nearly 23,000 times.

Tudor received his M.D. in general medicine (1990) and Ph.D. in molecular physiology (1992) from the University of Medicine and Pharmacy in Timişoara, Romania.